Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 3,473 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention II Clear all

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Bladder Cancer AJCC v8, MTAP Deletion
Interventions: Biospecimen Collection, Computed Tomography, Pemetrexed; Procedure · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Chicago, Illinois • Orland Park, Illinois

Conditions: Endometrial Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage I Uterine Sarcoma, Stage II Uterine Corpus Cancer, Stage II Uterine Sarcoma
Interventions: Laparoscopic Surgery, Quality-of-Life Assessment, Therapeutic Conventional Surgery; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: breast imaging study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: educational intervention, questionnaire administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: VB11, Surgery, Placebo, Bevacizumab; Drug · Procedure · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more

Conditions: Sedentary Behavior / Physical Inactivity, Aged
Interventions: Wearable Ankle Power Training (WearAPT), Control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 60 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Flagstaff, Arizona • Chapel Hill, North Carolina

Conditions: Leukemia, Lymphoma, Myeloma
Interventions: Busulfan, Fludarabine, Campath, Stem Cell Transplant; Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma
Interventions: rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 29
States / cities: Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more

Conditions: Colorectal Carcinoma
Interventions: Best Practice, Consultation, Educational Intervention, Electronic Health Record Review, Fecal Immunochemical Test, Feedback, Health Education, Support Education Activity, Text Message-Based Navigation Intervention; Other · Behavioral
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 9,745 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myelodysplastic Syndrome
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 149
States / cities: Berkeley, California • Irvine, California • Orange, California + 122 more

Conditions: Malignant Digestive System Neoplasm
Interventions: Best Practice, Health Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment; Other · Behavioral
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 55
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Survey Administration, Telisotuzumab Vedotin; Procedure · Drug · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bladder Cancer
Interventions: biopsy, therapeutic conventional surgery; Procedure
Lead sponsor: Roei Medical Technologies Ltd.; Industry
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Cutaneous Dysplastic Nevus
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration, Sulforaphane; Procedure · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Septic Shock
Interventions: Angiotensin II, Vasopressin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Caregiver
Interventions: Psychosocial Support for Caregiver, Questionnaire Administration, Sham Intervention; Other
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes, Obesity
Interventions: Program ENERGY, comparison; Behavioral · Other
Lead sponsor: Colorado State University; Other
Eligibility: 6 Years to 13 Years
Enrollment: 2,909 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Head and Neck Cancer, Stage I Hypopharyngeal Cancer, Stage I Laryngeal Cancer, Stage I Oropharyngeal Cancer, Stage II Hypopharyngeal Cancer, Stage II Laryngeal Cancer, Stage II Oropharyngeal Cancer, Stage III Hypopharyngeal Cancer, Stage III Laryngeal Cancer, Stage III Oropharyngeal Cancer, Stage IV Hypopharyngeal Cancer, Stage IV Laryngeal Cancer, Stage IV Oropharyngeal Cancer
Interventions: exercise intervention, questionnaire administration, quality-of-life assessment; Behavioral · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Metastatic Bone Lesion
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Paul W. Read, MD; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders
Interventions: acupuncture therapy, sham intervention; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Post-inflammatory Hyperpigmentation
Interventions: Tricholoacetic Acid (TCA); Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Prostate Cancer
Interventions: recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium, isotretinoin, polyacrylamide gel electrophoresis, protein expression analysis, immunohistochemistry staining method; Biological · Drug · Genetic + 1 more
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
Interventions: MEDI0457, Durvalumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania

Search by objective public record fields.

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus

Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer

Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Wearable Ankle Power Training (WearAPT) for Enhanced Mobility in Aging

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Perioperative Telemonitoring to Optimize Cancer Care and Outcomes

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection

Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Angiotensin II vs. Vasopressin in Septic Shock

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

Obesity and Diabetes Prevention Through Science Enrichment

Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer

Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

An In Vivo Model for Postinflammatory Hyperpigmentation

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients